January 2004 in “Pharmaceutical biotechnology” Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.
July 2023 in “World Journal of Biology Pharmacy and Health Sciences” Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.
January 2013 in “CINECA IRIS Institutial research information system (University of Pisa)” 3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
January 2013 in “International journal of contemporary surgery” Using Cyproterone Acetate with Eflornithine together is safe and works better for treating facial hair in women.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
25 citations
,
June 2002 in “Steroids” 4-azasteroids, including finasteride, can inhibit 5α-reductase, helping treat conditions like enlarged prostate and hair loss.
4 citations
,
January 2006 in “PubMed” DHT deficiency may disrupt rat epididymis function by affecting estrogen receptors.
20 citations
,
August 2014 in “Talanta” The method effectively measures drug impact on DHT levels in prostate treatments.
30 citations
,
March 2016 in “European Journal of Pharmaceutical Sciences” Optimized film improves finasteride skin absorption and treatment efficiency.
13 citations
,
October 2005 in “Analytical Sciences” A new method was developed to measure and assess the activity and inhibition of the enzyme steroid 5α-reductase.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.
February 2010 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Finasteride can cause skin reactions, so dermatologists should be aware.
November 2020 in “International journal of pharmaceutical compounding” A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.
1 citations
,
October 2022 in “Iet Nanobiotechnology” The dutasteride nanoemulsion could improve hair loss treatment by enhancing drug penetration and retention in hair follicles.
The FDA did not approve a testosterone drug because of safety concerns.
30 citations
,
July 2009 in “Experimental and clinical endocrinology & diabetes” Cyproterone acetate effectively treats sexual disorders by reducing sexual functions and is generally well-tolerated.
4 citations
,
September 2010 in “Medical Hypotheses”
8 citations
,
October 1998 in “Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology” Proscar (finasteride) blocks 5α-reductase in sea urchin ovaries and testes, suggesting potential treatment for androgen-related conditions.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
22 citations
,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
July 2025 in “Annals of Medicine” Gestrinone pellets may help reduce pelvic pain in endometriosis safely.
9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
2 citations
,
March 2016 in “The Journal of Urology” Finasteride 1mg linked to diverse symptoms; other treatments improve erectile function in rats.
12 citations
,
August 2017 in “Pharmaceutical medicine” Most doctors know the thrombosis risk with Cyproterone/Ethinylestradiol, but some lack details on less common risks and patient instructions; educational materials are underused but useful.
1 citations
,
January 2003 in “Chinese Journal of Pharmaceuticals” A new method to make Finasteride is more cost-effective and yields 16%.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
The paper suggests that a decrease in estrogen receptor activity may cause sexual dysfunction syndromes and proposes hormonal treatments.